# Encore PFO Closure Device - The PerFOrm Trial

Study · id `cardio:ct-nct05537753` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05537753](<https://clinicaltrials.gov/study/NCT05537753>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05537753

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

## Technical summary

Registry record NCT05537753. Randomized; no masking; primary purpose treatment. Start 2023-07-12 (actual); primary completion 2026-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT05537753, source copy `cardio:ctgov-nct05537753-2024-09-19`, retrieved 2026-10-26)
- Started: 2023-07-12 (actual) (ClinicalTrials.gov record NCT05537753, source copy `cardio:ctgov-nct05537753-2024-09-19`, retrieved 2026-10-26)
- Primary completion: 2026-04 (anticipated) (ClinicalTrials.gov record NCT05537753, source copy `cardio:ctgov-nct05537753-2024-09-19`, retrieved 2026-10-26)
- Completion: 2030-10 (anticipated) (ClinicalTrials.gov record NCT05537753, source copy `cardio:ctgov-nct05537753-2024-09-19`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05537753, source copy `cardio:ctgov-nct05537753-2024-09-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05537753-2024-09-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Encore PFO Closure Device - The PerFOrm Trial
- Condition: Patent Foramen Ovale
- Condition: Cryptogenic Stroke
- Intervention (Device): Encore PFO closure device
- Intervention (Device): FDA-approved PFO closure device
- Lead sponsor: Encore Medical Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Bright Research Partners
- Collaborator class: INDUSTRY
- Collaborator: Yale Cardiovascular Research Group
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as a collaborator: Bright Research Partners (`cardio:org-bright-research-partners`)
- Registry lists this organization as a collaborator: Yale Cardiovascular Research Group (`cardio:org-yale-cardiovascular-research-group`)

## Provenance

Content hash: 54f9a15a5e60f55632e420360e8d701c3d87d46ff80a3c54040ac6f27e8f8d75
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
